Mitochondrial DNA content as a diagnostic marker for antituberculosis drug-induced liver injury

Mitochondrial DNA content as a diagnostic marker for antituberculosis drug-induced liver injury

Objectives: This study aimed to investigate whether mitochondrial DNA (mtDNA) content, an index of mitochondrial dysfunction, was associated with clinical parameters indicating anti-tuberculosis (TB) drug-induced liver injury (ATDILI) in TB patients and could emerge as an ATDILI biomarker. Methods:...

Full description

Bibliographic Details
Main Authors:	Wanvisa Udomsinprasert, Jiraphun Jittikoon, Usa Chaikledkaew, Wacharapol Saengsiwaritt, Noppadol Chanhom, Supharat Suvichapanich, Sukanya Wattanapokayakit, Surakameth Mahasirimongkol, Wasun Chantratita
Format:	Article
Language:	English
Published:	Elsevier 2022-09-01
Series:	International Journal of Infectious Diseases
Subjects:	Mitochondrial DNA content Antituberculosis drug-induced liver injury Tuberculosis Biomarker
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971222004647

Similar Items

CYP2E1, GSTM1, and GSTT1 genetic polymorphisms and their associations with susceptibility to antituberculosis drug-induced liver injury in Thai tuberculosis patients
by: Noppadol Chanhom, et al.
Published: (2021-04-01)

Leukocyte telomere length as a diagnostic biomarker for anti-tuberculosis drug-induced liver injury
by: Wanvisa Udomsinprasert, et al.
Published: (2020-03-01)

Global DNA hypomethylation of Alu and LINE-1 transposable elements as an epigenetic biomarker of anti-tuberculosis drug-induced liver injury
by: Wanvisa Udomsinprasert, et al.
Published: (2021-01-01)

Effect of vitamin D supplementation on circulating level of autophagosome protein LC3A, inflammation, and physical performance in knee osteoarthritis
by: Wacharapol Saengsiwaritt, et al.
Published: (2023-12-01)

The Association of <i>HLA-B*35</i> and <i>GSTT1</i> Genotypes and Hepatotoxicity in Thai People Living with HIV
by: Noppadol Chanhom, et al.
Published: (2022-06-01)

Antituberculosis Drug-induced Hepatotoxicity in Pediatric Tuberculosis
by: Vycke Yunivita, et al.
Published: (2019-10-01)

Host genetic polymorphisms involved in long-term symptoms of COVID-19
by: Wanvisa Udomsinprasert, et al.
Published: (2023-12-01)

Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges
by: Monica Meloni, et al.
Published: (2015-12-01)

New antituberculosis drugs: from clinical trial to programmatic use
by: Gina Gualano, et al.
Published: (2016-06-01)

Hypersensitivity reactions with first-line antituberculosis drugs and outcomes of rapid desensitizations
by: Gozde Koycu Buhari, MD, et al.
Published: (2024-01-01)

Epidemiology of tuberculosis and susceptibility to antituberculosis drugs in Reunion Island
by: Moreea Loukman, et al.
Published: (2023-01-01)

Economic cost of patients with trisomy 13, 18, and 21 in a tertiary hospital in Thailand.
by: Preechaya Wongkrajang, et al.
Published: (2023-01-01)

Economic cost of patients with trisomy 13, 18, and 21 in a tertiary hospital in Thailand
by: Preechaya Wongkrajang, et al.
Published: (2023-01-01)

Tuberculous ulcer of tongue with oral complications of oral antituberculosis therapy
by: Ajay G, et al.
Published: (2006-01-01)

Protein kinases as antituberculosis targets: The case of thymidylate kinases
by: Sudarkodi Sukumar, et al.
Published: (2020-03-01)

Incidence and Clinical Profile of Antituberculosis Treatment-Induced Hepatitis in a Tertiary Care Hospital in Southern India
by: TP Jai Juganya, et al.
Published: (2020-10-01)

Safety Evaluation of Antituberculosis Drugs During Pregnancy: A Systematic Review and Meta-Analysis
by: Xiaomei Zhou, et al.
Published: (2022-04-01)

Incidence and characteristics of antituberculosis drug-induced hepatotoxicity in children: a preliminary study
by: Bina Akura, et al.
Published: (2009-12-01)

Greener Synthesis, In-Silico and Theoretical Analysis of Hydrazides as Potential Antituberculosis Agents (Part 1)
by: Suraj N. Mali, et al.
Published: (2021-11-01)

A Study of Embryotoxic, Foetotoxic, and Teratogenic Effects of the Original Antituberculosis Agent Thiozonide in Pregnant Rabbits
by: A. Yu. Borodina, et al.
Published: (2023-06-01)

Treatment in Latent Tuberculosis Uveitis—Is Immunosuppression Effective or Is Conventional 3- or 4-Drug Antituberculosis Therapy Mandatory?
by: Eileen Bigdon, et al.
Published: (2022-04-01)

Economic evaluation of prenatal screening for fetal aneuploidies in Thailand.
by: Preechaya Wongkrajang, et al.
Published: (2023-01-01)

Cartilage oligomeric matrix protein as a marker of progressive liver fibrosis in biliary atresia
by: Wanvisa Udomsinprasert, et al.
Published: (2021-08-01)

Cost-Utility Analysis of Molecular Testing for Tuberculosis Diagnosis in Suspected Pulmonary Tuberculosis in Thailand
by: Chitpim N, et al.
Published: (2022-02-01)

Unsuccessful antituberculosis medication treatment: A characteristic summarization in a suburban province with dense communities of Myanmar migrant worker in Bangkok Metropolitan Region, Thailand
by: Rujittika Mungmunpuntipantip, et al.
Published: (2019-01-01)

Impact of food intake on the pharmacokinetics of first-line antituberculosis drugs in Taiwanese tuberculosis patients
by: Hsien-Chun Lin, et al.
Published: (2014-05-01)

Human Serum Albumin Nanoparticles: Synthesis, Optimization and Immobilization with Antituberculosis Drugs
by: Aldana Galiyeva, et al.
Published: (2023-06-01)

Synthesis, structural studies and antituberculosis evaluation of new hydrazone derivatives of quinoline and their Zn(II) complexes
by: Mustapha C. Mandewale, et al.
Published: (2018-02-01)

Cholecalciferol for prophylaxis against antituberculosis therapy-induced liver disorders among naïve patients with pulmonary tuberculosis: A randomized, comparative study
by: Ahmad Farooq Alsayed Hasanain, et al.
Published: (2017-01-01)

Genetic mechanisms of co-emergence of INH-resistant Mycobacterium tuberculosis strains during the standard course of antituberculosis therapy
by: Ketema Tafess, et al.
Published: (2024-04-01)

Uric acid levels in patients on antituberculosis drugs in the southwest Region of Cameroon
by: Benjamin David Thumamo Pokam, et al.
Published: (2018-01-01)

Biosafety materials for tuberculosis treatment
by: Wei Wang, et al.
Published: (2022-08-01)

Propolis modulates cellular biochemistry, antioxidants, cytokine profile, histological and ultra-morphological status against antituberculosis drugs induced hepatic injury
by: Nisha Sahu, et al.
Published: (2018-01-01)

Uric acid levels in patients on antituberculosis drugs in the Southwest region of Cameroon
by: Benjamin D. Thumamo Pokam, et al.
Published: (2016-01-01)

Evaluation of crystal violet decolorization assay for minimal inhibitory concentration detection of primary antituberculosis drugs against Mycobacterium tuberculosis isolates
by: Ahmet Yilmaz Coban, et al.
Published: (2016-01-01)

Pharmacokinetics of isoniazid and rifapentine in young pediatric patients with latent tuberculosis infection
by: Weeraya Phaisal, et al.
Published: (2022-09-01)

A Case of Tuberculosis Septic Arthritis in the Knee Joint
by: Onur Ural, et al.
Published: (2018-12-01)

Synthesis and Biological Evaluation of Novel 2-Methoxypyridylamino-Substituted Riminophenazine Derivatives as Antituberculosis Agents
by: Dongfeng Zhang, et al.
Published: (2014-04-01)

Benefits of Therapeutic Drug Monitoring of First Line Antituberculosis Drugs
by: Prso K, et al.
Published: (2020-08-01)

Evaluation of theSusceptibility of Mycobacterium tuberculosis Complex Isolates Isolated from Clinical Specimens to Primer Antituberculous Drugs
by: Yeliz Tanriverdi Çaycı, et al.
Published: (2020-05-01)